Ultimate sensitivity PK assay for Alibion

Alibion’s ALB001 is an extremely potent compound which will be administered orally at low dose and not necessarily daily. This leads to extremely low concentrations in the blood which might not be measurable with conventional methods.

We are proud to announce that our innovative proposal has been chosen to help Alibion develop an ultrasensitive PK assay for assessing PK/PD relationship.

Alibion aims at closing the gap between highly interesting academic discoveries and the development of therapeutics through early stages. Its efforts are focused on identifying promising novel therapeutics and pooling the necessary resources to drive these compounds out of the labs and into late-stage development. Alibion strives to improve patient outcomes worldwide by bringing innovative therapeutics closer to patients.

Learn more about Alibion at www.alibion.com

This website is using cookies to improve the user-friendliness. You agree by using the website further.

Privacy policy